Acadia Achieves Successful Late-Stage Study, But Narrow Beat Highlights One Big Potential Change Moving Forward – ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)


Acadia Pharmaceuticals (ACAD) announced that it had achieved positive results from a pivotal study known as ADVANCE using its drug pimavanserin to treat negative symptoms of schizophrenia. The initial market reaction was mixed, based on narrowly achieving statistical significance. However, an opportunity exists to move forward. On top of that,Read More →